We share with the international scientific community, initially as a preprint in the MedRxiv repository, the results of the SoberanaPediatrics clinical trial. These data have worldwide relevance, they are excellent results in children 3-18 years old but particularly 3-11 years old, where there have been their skids out there.

Heterologous scheme with two doses of Soberana02 and one dose of SoberanaPlus, every 28 days.

Main evidence:

- Safe vaccination, no serious or severe events, only local pain had a frequency greater than 10%.

- 95% of children with seroconversion (4-fold increase of antibodies) after two doses, 100% after the third dose.

- Immune response with two doses of SOBERANA02 superior to that induced by natural infection (panel of convalescent children).

- Third dose with SoberanaPlus significantly increases all immunological variables.

- Neutralizing antibodies vs alpha, beta and delta, pending omicron.

- Virus-specific T-cell response.

- Non-inferiority (statistically) of neutralizing antibody response to young adults.

- Immunogenicity data predict a clinical efficacy higher than 90%, unthinkable for us to do a phase 3 (with placebo) in pediatrics.

This is why, from day zero, Soberana was designed for children. Here is the evidence of that bet.

Today, 1.8 million Cuban children and more than one million Nicaraguan children are happily vaccinated with Soberana.

The world will talk about this result, we will see it and we will all enjoy it together. For the moment, I will keep these photos, a few of the thousands that give us oxygen to continue.